A Pharmacokinetic Study of Avanfil in Healthy Young Male Subjects

Phase 1

Completed

• Conditions: Avanfil ADME; Semen Exposure; Sperm Function
• Interventions: Drug: avanafil 200mg

• Registration Number: NCT00914511
• Lead Sponsor: VIVUS LLC

Brief Summary

The purposes of this study are to:

* Determine the effect of the study drug on sperm and semen of healthy young male subjects.

* Determine the effect of age on the amount of study drug in the blood of healthy subjects

* Learn about the safety of the study drug.

* Learn how subjects tolerate the study drug.

Detailed Description

This single-center, open-label, non-randomized, two-cohort, single-dose pharmacokinetic study will be conducted at a single site in the United States, in which at least 18 young (18-45 years, inclusive) male subjects in Cohort A and 14 elderly (65 years or older) males in Cohort B will be enrolled and dosed to achieve a total of at least 14 completed young subjects and 12 elderly subjects. Seminal fluid and plasma will be collected from Cohort A, whereas only plasma samples will be collected from Cohort B.

Study Timeline

• Study Start: 2009-05
• Primary Completion: 2009-06
• Study Completion: 2009-06
• Study First Submitted: 2009-06-03
• Study First Submitted QC: 2009-06-04
• Study First Posted: 2009-06-05
• Status Verified: 2011-01
• Last Update Submitted: 2011-01-05
• Last Update Posted: 2011-01-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 32

Inclusion Criteria

• Cohort A: Adult male subjects of 18 to 45 years of age inclusive Cohort B: Adult male subjects at least 65 years of age
• All subjects must be medically healthy with no clinically significant screening results.
• Male subjects should be willing to use a condom and spermicide during sexual activity for 90 days after last dosing of Avanafil and be willing to not donate sperm for 90 days after dosing.

Exclusion Criteria

Major exclusion criteria for all subjects include:

• History or clinical evidence of clinically relevant cardiovascular (including thromboembolic disorders), hepatic, renal, hematologic, endocrine, pulmonary, gastrointestinal, psychiatric or neurological impairment
• Any clinically significant laboratory abnormalities as judged by the investigator
• Systolic blood pressure < 90 or >150 mmHg
• Diastolic blood pressure < 50 or > 95 mmHg
• Allergy to or previous adverse events with PDE5 inhibitors
• Use of prescription or over-the-counter drugs that are known to interfere with metabolism by the cytochrome P450 3A4 enzyme within 30 days of screening
• Use of any investigational drug within 30 days of screening
• Use of any prescription or over-the-counter drugs or herbal remedies within 14 days of screening
• History of alcohol or drug abuse within 18 months, history of smoking within 6 months
• Positive urine alcohol test
• Positive urine drug screen
• Positive urine cotinine test, positive serology for HIV, HCV, HBsAg
• Young males who have undergone vasectomy cannot participate in this-study
• Additional exclusion criteria are listed in Section 4.2.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Healthy young males	avanafil 200mg	Healthy young males age 18-45, inclusive
Elderly males	avanafil 200mg	Elderly males 65 years of age and older

Primary Outcome Measures

Name	Time	Method
Plasma pharmacokinetic parameters of avanafil and its metabolites will be evaluated including AUC (0-t), AUC(0-inf), Cmax, fu, t1/2, and tmax; Sperm motility, function and morphology; Avanafil exposure in seminal fluid	pre-dose (baseline) through 24 hours post-dose

Secondary Outcome Measures

Name	Time	Method
adverse events (each study visit); laboratory evaluations; electrocardiogram and physical examination; vital signs will be assessed at various times during the study.	pre-dose (baseline) through 24 hours post-dose

Trial Locations

Locations (1)

MDS Pharma Services; 🇺🇸 Tempe, Arizona, United States